#United States #New York #Levi & Korsinsky #Zenas BioPharma #ZBIO

Key Details of the Class Action against Zenas BioPharma, Inc.

On June 6, 2025, Levi & Korsinsky, LLP informed investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO) about a significant class action lawsuit based on allegations of securities fraud. This case centers around individuals who bought or acquired Zenas BioPharma securities, particularly related to their September 2024 initial public offering (IPO). The essence of the claim is that the company misrepresented its financial stability and the duration it could sustain operations using its existing cash and expected contributions from the IPO. The complaint argues that such misstatements deceived investors, leading to financial losses.

Class Definition

The lawsuit is designed to recompense investors impacted by the alleged misconduct of Zenas BioPharma's management. Given the complexity and scale of the issue, those who have suffered losses are encouraged to evaluate their involvement in this matter, particularly if they engaged in stock transactions around the time of the IPO.

Important Case Details

According to the filed complaint, the defendants made statements that were inaccurate and/or concealed significant information. It is argued that they overstated their operational funding timeline. As a result, public statements made by the organization were considered materially false and misleading, which eventually led to collective damages for the investors.

Next Steps for Investors

If you experienced financial losses in Zenas BioPharma during the specified period, you must act quickly. The deadline to apply for lead plaintiff status is June 16, 2025. Being appointed as the lead plaintiff provides an opportunity to steer the litigation but is not a requirement for participating in potential recoveries.

No Cost to Participate

Investors should note that participation in the class action carries no financial burden. Claimants may be eligible for compensation without any upfront fees or expenses. This class action is structured to ensure that members can seek restitution without initiating personal litigation or incurring costs.

Why Choose Levi & Korsinsky

With over two decades dedicated to representing shareholders, Levi & Korsinsky has built a robust reputation in securing substantial settlements for aggrieved investors. Their history includes winning high-profile cases and being recognized as one of the top securities litigation firms in the U.S. for multiple years. The firm employs a specialized team that focuses on complex securities litigation, ensuring clients receive competent representation.

Contact Information

If you find yourself as a prospective plaintiff in this case or need further details, direct inquiries to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP. You can reach out either via email at [email protected] or by phone at (212) 363-7500.

Company's Commitment to Transparency

Zenas BioPharma's current litigative environment highlights the critical importance of corporate transparency and accurate reporting. This class action reinforces that both companies and their representations to investors are held to strict accountability standards. The outcome of this lawsuit may not only affect current shareholders but also influence potential investors' perceptions moving forward.

Investors involved in this litigation must stay informed of updates and ensure that they meet any necessary deadlines so they can protect their interests while seeking justice for the alleged wrongs committed by Zenas BioPharma.